Sort by
Previous Page Page 1 of 9 Next Page
  1. Research

    Antibiotic use during pregnancy: a retrospective study of prescription patterns and birth outcomes at an antenatal clinic in rural Ghana

    Babies are increasingly being exposed to antibiotics intrapartum in the bid to reduce neonatal and maternal deaths. Intrapartum antibiotic exposure, including even those considered safe in pregnancy, have been...

    Kwesi Boadu Mensah, Kwame Opoku-Agyeman and Charles Ansah

    Journal of Pharmaceutical Policy and Practice 2017 10:24

    Published on: 9 August 2017

  2. Research

    Drug utilization patterns among elderly hospitalized patients on poly-pharmacy in Punjab, Pakistan

    Reports from drug utilization reviews are important tools employed in the assessment of healthcare practices. The objective of this study was to evaluate drug utilization patterns among elderly hospitalized pa...

    Muhammad Rehan Sarwar, Muhammad Atif, Shane Scahill, Anum Saqib, Muhammad Qamar-uz-Zaman and Zaheer Babar

    Journal of Pharmaceutical Policy and Practice 2017 10:23

    Published on: 4 August 2017

  3. Commentary

    Taking the lead from our colleagues in medical education: the use of images of the in-vivo setting in teaching concepts of pharmaceutical science

    Despite pharmaceutical sciences being a core component of pharmacy curricula, few published studies have focussed on innovative methodologies to teach the content. This commentary identifies imaging techniques...

    Louise E. Curley, Julia Kennedy, Jordan Hinton, Ali Mirjalili and Darren Svirskis

    Journal of Pharmaceutical Policy and Practice 2017 10:22

    Published on: 17 July 2017

  4. Research

    Exploring the status of retail private drug shops in Bangladesh and action points for developing an accredited drug shop model: a facility based cross-sectional study

    The private retail drug shops market in Bangladesh is largely unregulated and unaccountable, giving rise to irrational use of drugs and high Out-of-pocket expenditure on health. These shops are served by sales...

    Syed Masud Ahmed, Nahitun Naher, Tarek Hossain and Lal Bahadur Rawal

    Journal of Pharmaceutical Policy and Practice 2017 10:21

    Published on: 11 July 2017

  5. Review

    The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review

    Smoking is the number one cause of preventable morbidity and mortality globally and although many countries have invested heavily in smoking cessation programs, 21% of the global population still smoke. Post c...

    Raewyn Rees and Ali Seyfoddin

    Journal of Pharmaceutical Policy and Practice 2017 10:20

    Published on: 11 July 2017

  6. Review

    Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

    The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agree...

    Ellen F. M. ‘t Hoen, Pascale Boulet and Brook K. Baker

    Journal of Pharmaceutical Policy and Practice 2017 10:19

    Published on: 28 June 2017

  7. Research

    Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance

    Barriers to expanding access to medicines include weak pharmaceutical sector governance, lack of transparency and accountability, inadequate attention to social services on the political agenda, and financing ...

    Taryn Vian, Jillian C. Kohler, Gilles Forte and Deirdre Dimancesco

    Journal of Pharmaceutical Policy and Practice 2017 10:18

    Published on: 2 June 2017

  8. Research

    Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies

    Many middle-income countries are scaling up health insurance schemes to provide financial protection and access to affordable medicines to poor and uninsured populations. Although there is a wealth of evidence...

    Warren A. Kaplan, Paul G. Ashigbie, Mohamad I. Brooks and Veronika J. Wirtz

    Journal of Pharmaceutical Policy and Practice 2017 10:17

    Published on: 16 May 2017

  9. Research

    Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review

    Medicines use related challenges such as inadequate adherence, high levels of antimicrobial resistance and preventable adverse drug reactions have underscored the need to incorporate pharmaceutical services to...

    Niranjan Konduri, Megan Rauscher, Shiou-Chu Judy Wang and Tanya Malpica-Llanos

    Journal of Pharmaceutical Policy and Practice 2017 10:16

    Published on: 8 May 2017

  10. Research

    Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana

    The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in ...

    Alexander Freeman, Anthony Kwarteng, Lawrence Gyabaa Febir, Seeba Amenga-Etego, Seth Owusu-Agyei and Kwaku Poku Asante

    Journal of Pharmaceutical Policy and Practice 2017 10:15

    Published on: 28 April 2017

  11. Policy Analysis

    Drug pricing and reimbursement decision making systems in Mongolia

    It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently,...

    Gereltuya Dorj, Bruce Sunderland, Tsetsegmaa Sanjjav, Gantuya Dorj and Byambatsogt Gendenragchaa

    Journal of Pharmaceutical Policy and Practice 2017 10:11

    Published on: 27 February 2017

  12. Commentary

    The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications

    When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation....

    Eline M. Bunnik, Nikkie Aarts and Suzanne van de Vathorst

    Journal of Pharmaceutical Policy and Practice 2017 10:10

    Published on: 21 February 2017

  13. Research

    Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients

    Lack of regulatory capacity limits the conduct of ethical and rigorous trials of herbal medicines in developing countries. Sharing ethical and regulatory experiences of successful herbal trials may accelerate ...

    Tsitsi G. Monera-Penduka, Charles C. Maponga, Gene D. Morse and Charles F. B. Nhachi

    Journal of Pharmaceutical Policy and Practice 2017 10:9

    Published on: 20 February 2017

  14. Research

    Civil society engagement in multi-stakeholder dialogue: a qualitative study exploring the opinions and perceptions of MeTA members

    The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordabili...

    Gemma L. Buckland-Merrett, Catherine Kilkenny and Tim Reed

    Journal of Pharmaceutical Policy and Practice 2017 10:5

    Published on: 6 January 2017

  15. Research

    Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study

    The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focus...

    Rumiko Shimazawa and Masayuki Ikeda

    Journal of Pharmaceutical Policy and Practice 2017 10:4

    Published on: 6 January 2017

  16. Research

    The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

    This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r)...

    Jörg Mahlich, Mona Groß, Alexander Kuhlmann, Johannes Bogner, Hans Heiken and Matthias Stoll

    Journal of Pharmaceutical Policy and Practice 2016 9:39

    Published on: 30 December 2016

  17. Research

    Assessing medication packaging and labelling appropriateness in Sri Lanka

    There is substantial evidence of poor dispensing practices with inadequate packaging and labelling of medicines, and limited advice on their usage in low and middle-income countries (LMICs). We examined the la...

    N. Athuraliya, E. J. Walkom, S. Dharmaratne and J. Robertson

    Journal of Pharmaceutical Policy and Practice 2016 9:38

    Published on: 25 November 2016

  18. Commentary

    Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

    The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation o...

    Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavetti and Jean-Michel Caudron

    Journal of Pharmaceutical Policy and Practice 2016 9:36

    Published on: 10 November 2016

Previous Page Page 1 of 9 Next Page